DK2666475T3 - Terapeutisk middel til skaldethed - Google Patents

Terapeutisk middel til skaldethed

Info

Publication number
DK2666475T3
DK2666475T3 DK12736336.4T DK12736336T DK2666475T3 DK 2666475 T3 DK2666475 T3 DK 2666475T3 DK 12736336 T DK12736336 T DK 12736336T DK 2666475 T3 DK2666475 T3 DK 2666475T3
Authority
DK
Denmark
Prior art keywords
boldness
therapeutic agent
therapeutic
agent
Prior art date
Application number
DK12736336.4T
Other languages
English (en)
Inventor
Kyoko Endo
Original Assignee
Igisu Co Ltd
Endo Yori
Kyoko Endo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igisu Co Ltd, Endo Yori, Kyoko Endo filed Critical Igisu Co Ltd
Application granted granted Critical
Publication of DK2666475T3 publication Critical patent/DK2666475T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Pulmonology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK12736336.4T 2011-01-21 2012-01-20 Terapeutisk middel til skaldethed DK2666475T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011011437 2011-01-21
PCT/JP2012/051272 WO2012099258A1 (ja) 2011-01-21 2012-01-20 脱毛症治療剤

Publications (1)

Publication Number Publication Date
DK2666475T3 true DK2666475T3 (da) 2017-11-20

Family

ID=46515875

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12736336.4T DK2666475T3 (da) 2011-01-21 2012-01-20 Terapeutisk middel til skaldethed

Country Status (14)

Country Link
US (4) US20120238498A1 (da)
EP (2) EP3269382A1 (da)
JP (1) JP5261620B2 (da)
KR (1) KR101954869B1 (da)
CN (2) CN110801514A (da)
AU (2) AU2012207816B2 (da)
BR (1) BR112013018679B1 (da)
CA (1) CA2825382C (da)
DK (1) DK2666475T3 (da)
ES (1) ES2647680T3 (da)
HU (1) HUE035584T2 (da)
MX (1) MX353295B (da)
TW (2) TWI619505B (da)
WO (1) WO2012099258A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208756A1 (en) 2009-07-23 2012-08-16 Igisu Co., Ltd Composition for external preparation for skin
MX353295B (es) 2011-01-21 2018-01-08 Endo Kyoko Agente para el tratamiento de la alopecia.
KR101833776B1 (ko) * 2015-04-28 2018-03-02 (주) 메드빌 지모와 두릅의 복합 추출물을 함유하는 탈모 방지 및 발모 개선용 조성물
CA2986086A1 (en) * 2015-05-29 2016-12-08 Igisu Co., Ltd. Cyclyc peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
JP7253220B2 (ja) * 2015-07-31 2023-04-06 株式会社 イギス Cnp環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
CN105617360B (zh) * 2015-12-04 2018-12-21 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
US11357783B2 (en) * 2016-03-18 2022-06-14 Caregen Co., Ltd. Conjugate of finasteride with peptide
CA3018561A1 (en) * 2016-03-21 2017-09-28 Rhode Island Council On Postsecondary Education Ph-sensitive peptides
US11312758B2 (en) 2016-08-18 2022-04-26 National University Of Singapore Peptides with vasodilatory and/or diuretic functions
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
GB2568849B (en) 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
EP3509572A4 (en) * 2016-09-08 2020-05-13 Synergistic Therapeutics, LLC TOPICAL FORMULATION FOR HAIR GROWTH
CN108424446A (zh) * 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 新的重组人心房利钠肽突变体的制备及其应用
JP2021521264A (ja) * 2018-02-28 2021-08-26 マザーズ ファーマシューティカル カンパニー リミテッド 脱毛治療及び発毛促進用組成物
CN109011138A (zh) * 2018-05-07 2018-12-18 北京全贵医疗科技有限公司 基于头部图像的头部理疗方法及装置
WO2020123312A1 (en) 2018-12-09 2020-06-18 Weinberg Assa Method to prevent and treat macular degeneration by vasodilators
WO2020154304A1 (en) * 2019-01-24 2020-07-30 Weinberg Assa Method to prevent and treat alopecia by calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers
JP7575722B2 (ja) * 2019-10-28 2024-10-30 大正製薬株式会社 外用医薬組成物
CA3249528A1 (en) * 2022-04-19 2023-10-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Peptides to promote hair follicle neogenesis and prevent/mitigate the undesirable effects of radiation treatment
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도
KR102890438B1 (ko) * 2023-10-16 2025-11-25 (주)뉴트리 탈모 증상 완화능을 갖는 두피 유래 펩타이드

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804650A (en) 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
US5047397A (en) 1988-08-26 1991-09-10 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Cnp類似体ペプチド
JPH05207891A (ja) 1991-03-08 1993-08-20 Shionogi & Co Ltd 脳性ナトリウム利尿ペプチドの製造方法
WO1994020534A1 (en) 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
US5965533A (en) 1997-05-23 1999-10-12 Baxter International Inc. Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis solutions
JP3799465B2 (ja) 1998-09-28 2006-07-19 参天製薬株式会社 ナトリウム利尿ペプチドを有効成分とする涙液分泌促進または角結膜障害治療用点眼剤
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
WO2004022003A2 (en) 2002-09-06 2004-03-18 University Of South Florida Materials and methods for treatment of allergic diseases
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US7887842B2 (en) 2003-02-07 2011-02-15 Teikoku Pharma Usa, Inc. Methods of administering a dermatological agent to a subject
CN1816353B (zh) 2003-06-13 2010-05-05 阿斯比奥制药株式会社 用于预防或治疗Th1型免疫疾病的药物组合物
KR100509446B1 (ko) 2003-06-19 2005-08-22 세메스 주식회사 반도체 제조 공정에서 사용되는 약액 공급 장치
WO2005000095A2 (en) 2003-06-20 2005-01-06 Mayo Foundation For Medical Education And Research Isoforms of brain natriuretic peptide
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
CA2554599A1 (en) 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof
JP2007525213A (ja) 2004-01-27 2007-09-06 コンピュゲン ユーエスエイ,インク. 新規の脳性ナトリウム利尿ペプチドの変異体及びその利用方法
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
WO2005094890A1 (ja) 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
WO2006020841A2 (en) * 2004-08-11 2006-02-23 Alza Corporation Apparatus and method for transdermal delivery of natriuretic peptides
EP1810716A1 (de) 2005-12-23 2007-07-25 Deutsches Zentrum für Luft- und Raumfahrt e.V. Verfahren zur Bräunung der Haut
US7196223B2 (en) * 2005-05-03 2007-03-27 Solutia, Inc. Higher alcohols for solvents in amine production
JP3830960B1 (ja) * 2005-08-12 2006-10-11 建仁 河乃 育毛物質
CN101501067B (zh) 2006-08-08 2013-01-16 梅约医学教育与研究基金会 利尿和利尿钠的多肽
JPWO2008032450A1 (ja) 2006-09-15 2010-01-21 国立大学法人京都大学 脂肪肝の予防剤および/または治療剤
KR100842392B1 (ko) 2006-10-10 2008-07-01 주식회사 일진글로벌 토크를 측정할 수 있는 구동휠시스템
JP2008140125A (ja) 2006-12-01 2008-06-19 Rakuten Inc サービス予約システム、予約登録装置、参加者募集方法及び参加者募集処理プログラム
WO2008082524A1 (en) 2006-12-19 2008-07-10 National Stem Cell Inc. Embryonic germ cell secreted product derived topical compositions and methods of use thereof
JP5010913B2 (ja) * 2006-12-31 2012-08-29 寿子 小出 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
JP2010168283A (ja) 2007-04-24 2010-08-05 Yamaguchi Univ ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤
JP5207316B2 (ja) 2007-05-10 2013-06-12 国立大学法人名古屋大学 腹膜線維化抑制用医薬組成物
JP2009013122A (ja) * 2007-07-06 2009-01-22 Masaru Okura 育毛剤
US20100204145A1 (en) 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
JP2010539002A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト ウロジラチンの治療剤としての使用
EP2217620A2 (en) 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
US8455438B2 (en) * 2008-12-29 2013-06-04 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
US20110014180A1 (en) * 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
US20120208756A1 (en) * 2009-07-23 2012-08-16 Igisu Co., Ltd Composition for external preparation for skin
WO2011024973A1 (ja) * 2009-08-27 2011-03-03 株式会社 イギス 鼻炎治療剤
MX353295B (es) 2011-01-21 2018-01-08 Endo Kyoko Agente para el tratamiento de la alopecia.

Also Published As

Publication number Publication date
TWI619505B (zh) 2018-04-01
US9480728B2 (en) 2016-11-01
CA2825382A1 (en) 2012-07-26
EP3269382A1 (en) 2018-01-17
TW201244734A (en) 2012-11-16
BR112013018679B1 (pt) 2022-04-12
US11571464B2 (en) 2023-02-07
EP2666475A1 (en) 2013-11-27
EP2666475A4 (en) 2014-12-31
MX2013008422A (es) 2013-10-03
US20180133289A1 (en) 2018-05-17
EP2666475A8 (en) 2014-03-19
CN103547282A (zh) 2014-01-29
TW201811360A (zh) 2018-04-01
CN110801514A (zh) 2020-02-18
ES2647680T3 (es) 2017-12-26
US20170065680A1 (en) 2017-03-09
MX353295B (es) 2018-01-08
US20140315810A1 (en) 2014-10-23
JPWO2012099258A1 (ja) 2014-06-30
US20120238498A1 (en) 2012-09-20
KR101954869B1 (ko) 2019-05-30
WO2012099258A1 (ja) 2012-07-26
AU2012207816A1 (en) 2013-08-22
AU2017203793A1 (en) 2017-06-22
JP5261620B2 (ja) 2013-08-14
EP2666475B1 (en) 2017-08-16
BR112013018679A2 (pt) 2016-10-18
AU2012207816B2 (en) 2017-03-09
US9808511B2 (en) 2017-11-07
HUE035584T2 (en) 2018-05-28
KR20140041437A (ko) 2014-04-04
CA2825382C (en) 2020-07-28

Similar Documents

Publication Publication Date Title
DK2666475T3 (da) Terapeutisk middel til skaldethed
CO6801645A2 (es) Nuevos inmunoconjugados
EP2782540A4 (en) CHAIR WITH ROLLERS
DK2694038T3 (da) Farmaceutisk sammensætning
EP2663304A4 (en) COMBINATION THERAPY
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
BR112014002399A2 (pt) conjunto
DK2769050T3 (da) Propsensor
DE102011100082A8 (de) Traygreifvorrichtung
DK2760886T3 (da) Immunocytokin-kombinationsterapi
EP2726095A4 (en) COMBINATION THERAPY
FI20115876A0 (fi) Yhdistelmähoito
CO6960543A2 (es) 2-tiopirimidinonas
DK2849760T3 (da) Fremgangsmåder til oligonukleotid-chelatkompleks
DK3141251T3 (da) Koloskopi - forberedelse
BR112014009319A2 (pt) compostos farmacêuticos
EP2860233A4 (en) PUNCTURE CLOSURE MEANS
IL229081A0 (en) Isoxazolines as therapeutic agents
CO6880064A2 (es) Métodos terapéuticos
DE112011104936A5 (de) Stanzstauchniet
DE112012000958A5 (de) Handsäge
FI20115640A0 (fi) Yhdistelmähoito
DE112013005825A5 (de) Reduktionsmittelzuführeinrichtung
DK2476953T3 (da) Fluidbedkedel
EP2687212A4 (en) DRUG